-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Joint Procurement Office previously informed that the results of the seventh batch of national procurement will be implemented in November 2022, and the specific implementation date will be subject
to the notice issued by various places.
Henan and Hainan have issued documents clarifying that the seventh batch of national procurement
will be implemented on November 1 and the end of November 2022.
Yunnan began to purchase drugs with defective specifications in quantity, and Hebei clearly required the completion of qualification and price declaration from
October 12 to 16.
On July 18, the State Joint Procurement Office issued a notice
on the results of the seventh batch of national procurement.
According to the announcement, the results of this collective procurement will be implemented in November 2022, and the specific implementation date will be subject
to the notice issued by various places.
The procurement of 60 drugs was successful, and the average price of the selected drugs was reduced by 48%, involving 31 treatment categories, including not only hypertension, diabetes, anti-infection, digestive tract diseases and other common diseases, chronic diseases, but also lung cancer, liver cancer, kidney cancer, bowel cancer and other major diseases, according to the agreed procurement amount, it is expected to save 18.
5 billion yuan
per year 。 At present, each province has successively issued notices on the implementation of the seventh batch of national procurement, which is summarized as follows: Yunnan: 3 products with defective drugs are purchased with quantity, and the one with the lowest quotation is selected On October 11, Yunnan Province issued the "Announcement on the Seventh Batch of Centralized Procurement of Some Drugs with Defective Specifications in Yunnan Province", which made hepatanol injection (50ml: 18.
5g (I)), cefminol injection (0.
5g), The seventh batch of methylprednisolone oral regular-release dosage form (4mg) and other countries collected 3 defective drugs for quantitative procurement
.
The total pre-purchase volume of the three specifications is 3.
8283 million (tablets/capsules/bags/sticks), and the procurement subjects are medical institutions and medical insurance designated pharmacies
in the province.
In principle, the procurement cycle is one year
.
In terms of quotation, for the varieties selected by the national procurement but not selected to supply to Yunnan, the price shall be declared at a price
not higher than the national selection.
For those who meet the eligibility for drug declaration and have no state-organized centralized drug procurement selected price, the quotation is not higher than the price of selected drugs in Yunnan Province (different specifications are converted by the difference between the specifications of selected drugs).
In terms of selection rules, if there are two or more companies offering the same drug, and it meets the "declaration qualifications", the one with the lowest quotation will be selected
.
If the quotation of the enterprise is the same, the self-produced enterprise of the API is preferred
.
The selected drugs are included in the Yunnan Provincial Drug Centralized Procurement Platform Procurement Special Zone with Quantity, and relevant policies
such as prepayment of national centralized procurement funds and balance retention are implemented.
The selected enterprises select no more than 3 distribution enterprises for distribution on the centralized drug procurement platform of Yunnan Province and establish distribution relationships
.
If the selected variety is suspended by the drug regulatory department for production, sales, use, import, etc.
, the selected variety shall be disqualified
.
Hebei: Completion of qualification and price declaration from October 12 to 16 On October 12, the Hebei Provincial Medical Drug Device Centralized Procurement Center issued the Notice on Carrying out the Seventh Batch of Centralized Procurement of Selected Drugs in Hebei Region, requiring relevant pharmaceutical manufacturers to complete the qualification and price declaration from
October 12 to 16, 2022.
Those who fail to declare within the time limit shall be deemed to have voluntarily waived their qualifications
for this listing.
The selected drugs and alternative drugs in the seventh batch of national procurement Hebei must be declared, and the declared drug specifications and packaging must be within the scope of
the "National Centralized Drug Procurement Document (GY-YD2022-1)".
Selected drugs in other regions and non-selected drugs of the same variety who intend to be sold on the network in Hebei Province can also declare and be listed on the network
in accordance with the policies of our province.
If it is not traded on the centralized drug procurement platform of Hebei Province, it is necessary to declare the qualification and the lowest price in the country; If it has been traded on the centralized drug procurement platform of Hebei Province, it is necessary to re-declare the price of the network
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
